New study tracks lupus kidney drug safety in daily use

NCT ID NCT07053891

Recruiting now Disease control Sponsor: Otsuka Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study monitors the safety and effectiveness of the drug LUPKYNIS (voclosporin) in 400 adults with lupus nephritis under real-world conditions. Participants take LUPKYNIS alongside standard medications like steroids. The goal is to track side effects and see how well the drug works outside of a controlled research setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Voclosporin (LUPKYNIS)
What this could lead to: If successful, this study could confirm that LUPKYNIS is safe and effective for controlling lupus nephritis in everyday medical practice.
What could go wrong: This is an observational survey, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors like patient health or other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Pharmacovigilance Department
RECRUITING

Osaka, Osaka, 540-0021, Japan

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.